Latest Share Chat

REMOVE ADS

Plethora Solutions Holdings Plc Share Chat (PLE)

Plethora Solutions Holdings Plc Information

There is currently no data for PLE

REMOVE ADS

Some Videos You Might Like

What's Hot end of April

28th April 2026

Barclays

Chat Filters

You must be logged in to use filters Click here to login

Post Message

Post a Message

You must be logged in to post Click here to login

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".

By posting on our share chat boards you are agreeing to the following:

You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
- discuss illegal or criminal activities.
- post any confidential or price sensitive information or that is not public knowledge.
- post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
- post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
- post any personal details (e.g. email address or phone number).
- post live price or level 2 updates.
- publish content that is not your original work, or infringes the copyright or other rights of any third party.
- post non-constructive, meaningless, one word (or short) non-sense posts.
- post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
- post any affiliate or referral links, or post anything asking for a referral.
- post or otherwise publish any content unrelated to the board or the board's topic.
- re-post premium share chat posts on regular share chat.
- restrict or inhibit any other user from using the boards.
- impersonate any person or entity, including any of our employees or representatives.
- post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
- If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.

The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.

Please note some users may not behave properly and may post content that is misleading, untrue or offensive.

It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.

Premium and Verified Members

Premium Members are members that have a premium subscription with London South East. You can subscribe here.

London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.

Only showing the five most recent posts. Click here to view the whole thread.

REMOVE ADS

Only showing the five most recent posts. Click here to view the whole thread.

Only showing the five most recent posts. Click here to view the whole thread.

For the next 12 months: Senstend/Fortacin is far more important.

* For the next 3–5 years: Deep Longevity could become equally important if it gains commercial traction.

Deep Longevity generated only about US$135,000 of revenue in 2025, compared with the group’s total revenue of US$363,000.

That means today it contributes very little financially.

However, management is clearly treating it as a second growth engine alongside Fortacin. The company has:

* Expanded into China, India and Thailand.

* Started hiring a dedicated U.S. sales team.

* Identified the U.S. as its largest long-term market.

* Developed additional products such as FaceAge and BiometricAge.

The problem is that Deep Longevity is still at the commercialization stage rather than the proven-revenue stage.

What worries me

One detail in the filings stands out:

The Deep Longevity intellectual property was previously written down to nil value because management could not justify its carrying value based on projected cash flows.

That does not mean the business is worthless.

It means auditors and management could not support a large accounting valuation at the time.

So investors should not assume Deep Longevity is worth tens or hundreds of millions today.

What excites me

The U.S. launch is not just a website launch.

The company is hiring dedicated U.S. executives and targeting:

* Insurers

* Corporate wellness providers

* Diagnostic labs

* Longevity clinics

* Health platforms

Management has stated a goal of securing 50+ U.S. enterprise clients.

If they can sign even a handful of meaningful enterprise contracts, Deep Longevity could eventually become more valuable than Fortacin.

The challenge is that there is currently no evidence of large-scale commercial adoption.

⸻

My valuation scenarios

These are my estimates, not company forecasts.

Bear case (40%)

* China approval delayed again.

* Deep Longevity remains small.

* Continued cash strain.

Estimated value:

HK$0.30–1.00/share

Base case (40%)

* China approval obtained.

* US$5 million milestone received.

* Royalty income grows gradually.

* Deep Longevity gains customers but remains modest.

Estimated value:

HK$1.50–3.00/share

This is where I think the most realistic upside lies.

Bull case (15%)

* China launch succeeds.

* Royalties become meaningful.

* U.S. licensing progress for Fortacin.

* Deep Longevity signs major enterprise customers.

Estimated value:

HK$5–10/share

This is the scenario where long-term shareholders finally see substantial recovery.

Dream case (5% or less)

* China highly successful.

* U.S. FDA pathway resolved.

* Major pharma partnership.

* Deep Longevity becomes a recognized player in longevity analytics.

Good morning Jamie.

Thank you for the response to my email, which provides a little positivity.

Regarding the DBC, I apologise for my punctuation. A new paragraph was supposed to start with "Overnight", meaning: Overnight, the company (meaning RPG and not DBC) became Cannabinoid investors,... The email was written in word and copied over, so I can only assume some formatting was altered during the copy and paste process.

With regard to PSNW, although Recordati may have the responsibility to use their own manufacturer, it was quite obvious from the onset that they would use PSNW given that RPG had already stated in 2014 that PSNW was engaged as the Company’s European-based manufacturing partner, otherwise something else would have been stated regarding Recordati. As such, RPG had a responsibility to advise shareholders of the administration issues given they had a substantial impact on shareholder value from a necessary placing. If there were no issue and Recordati still wished to change manufacturer, PSNW could have still supplied cans whilst Recordati were entering into a new agreement with Genetic and obtaining EU approval. This would have had no delay with the European 2nd rollout China and Orient and more than likely no requirement for dilution given China would have had 18months of sales.

That’s said, there has been no update on progress with the change in manufacturer by Orient. Why was this? Ever since Orient entered into a license agreement, there appears to be little progress, which will now be further delayed due to the PSNW debacle. Has there been any progress on either of Orients regions with regard to approval progress?

With regard to production, you again only mention production possibilities but do not elaborate on current upscaling. The OTC approval announcement did mention upscaling to 50k cans, but given the wording used (with the aim), which is not that specific on timeline, one has to assume batches would still only be every 4 months. At least with PSNW we knew they had upscaled to 50k cans which could be produced every 6 to 7 weeks (you actually provided me with sometime ago a complete timeline breakdown on batch production). Can you please elaborate on what the current upscaling is or is it as I have indicated ?

Although Genetic is in the process of building an additional production line, this surely will take close to a couple of years before it is built, approved and up and running, which I base on the information you provided before with respect to a n additional production line with PSNW. Will the time needed by Genetic be any different and when are they targeting to complete this alleged work?

Continued.....

Many thanks for your email.

We fully recognise and share your disappointment regarding the EU sales performance by Recordati. By way of context, it may be helpful to reiterate the Company’s business model.

Regent Pacific operates a focused model centered on the development and strategic out-licensing of Fortacin / Senstend. The Group has successfully developed Fortacin through its in-house R&D platform and has subsequently entered into territorial licensing arrangements with established pharmaceutical partners.

Under these agreements, the Group receives upfront consideration, regulatory and commercial milestone payments, and ongoing royalties based on net sales within the licensed territories. Our partners assume full responsibility for all downstream activities, including manufacturing, regulatory approval, marketing, distribution and sales. The Group is not involved in these activities; they are undertaken by our partners at their own risk and cost, with the Company receiving the contracted economic benefits.

This partnership-led approach enables the Group to leverage the scale, infrastructure and commercial expertise of leading pharmaceutical companies, while maintaining a lean operating structure and a less capital intensive framework.

With respect to manufacturing, the contract manufacturing organisation (“CMO”) Genetic was engaged by Recordati. The Group does not contract directly with Genetic or any other CMO, and manufacturing risk and cost remain the responsibility of our pharmaceutical partners. We understand from Genetic that it has capacity to produce approximately 23 million Fortacin canisters per annum and is targeting an additional c.20 million units through a new PMDI production line currently under construction.

The license agreement with Recordati remains in force and unchanged since execution.

In China, our partner Fosun Pharma continues to progress the regulatory approval process. Based on their latest guidance, they remain hopeful of securing approval by the end of Q2. To date, Fosun has addressed over 35 queries from the NMPA and CDE across clinical, non-clinical and CMC sections and is progressing towards completion.

With regard to DLI, the business has currently secured eight customers, and further details are available on its website. The longevity sector remains at an early stage of development, and we are encouraged by the initial commercial traction achieved by a lean team.

Looking ahead, the potential approval of Senstend in China represents a significant opportunity for the Group, given the size of the market and Fosun’s view of the product’s commercial potential.

In parallel, we are actively engaging with potential strategic pharmaceutical partners for the US market who would undertake Phase III studies, regulatory approval and subsequent commercialisation. This remains a key strategic priority. ...... Continues